Topic
Biotech, longevity, implants, and health tech that fits the near-future beat.
10 stories
Companies
Newest
NASA and SpaceX are targeting 6:33 a.m. ET Tuesday, Oct. 13, for CRS-35. Dragon carries more than 6,300 pounds to the space station, including the last pair of new solar arrays and experiments that build artificial retinas, heart tissue, and brain organoids in orbit.
On Oct. 9, the FDA approved Hovilpri (pritelivir), an oral drug for immunocompromised adults whose herpes sores do not respond to standard antivirals. Asahi Kasei says it is the first approved option for these cases with a new mechanism in nearly 30 years.
On Oct. 8, the FDA approved Genentech's Tecentriq with chemo after surgery for stage III mismatch repair deficient colon cancer. In the ATOMIC trial, adding it cut the risk of the cancer returning or death by half, with more serious side effects.
A study published Oct. 7 in the New England Journal of Medicine treated 10 people blinded by advanced retinitis pigmentosa with an optogenetic gene therapy and special goggles. It was safe, seven became more sensitive to light, and some could find objects and doorways, though none got normal sight back.
On Oct. 7, the FDA approved Pfizer's Tukysa with trastuzumab and pertuzumab as first-line maintenance for advanced HER2-positive breast cancer. In the HER2CLIMB-05 trial, it pushed median progression-free survival from 16.3 to 24.9 months, with more liver side effects.
Bridge came out of stealth on Oct. 6 with $13.5 million, a license for Butterfly Network's ultrasound-on-a-chip, and a first human study in Redwood City. The plan is to read brain activity with sound, through the skull.
On Oct. 7 Cerevance said once-daily solengepras cut daily OFF time by 0.61 hours versus placebo in its 341-person ARISE trial, working through a new brain target called GPR6. Next stop is the FDA.
On Oct. 6 the Federal Register noticed a priority review voucher for FAYUVI, Ultragenyx's AAV9 gene therapy approved Sept. 17 for children with Sanfilippo syndrome type A.
Mid-September’s 23-second Neuralink video — captioned “A beautiful surprise” — shows speech decoding in a clinical trial, not a consumer product.
As the ISS winds down, drugmakers are lining up commercial stations and return capsules — and talking to regulators about medicine made in orbit.